Get the Stockscreener App
7.87
0.38%
0.03
After Hours:
7.90
0.03
+0.38%
Trevi Therapeutics Inc stock is traded at $7.87, with a volume of 1.65M.
It is up +0.38% in the last 24 hours and up +38.56% over the past month.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
See More
Previous Close:
$7.84
Open:
$7.89
24h Volume:
1.65M
Relative Volume:
0.92
Market Cap:
$923.10M
Revenue:
-
Net Income/Loss:
$-29.07M
P/E Ratio:
-27.14
EPS:
-0.29
Net Cash Flow:
$-31.85M
1W Performance:
+14.72%
1M Performance:
+38.56%
6M Performance:
+101.28%
1Y Performance:
+148.26%
1-Day Range:
$7.65
$7.97
1-Week Range:
$6.67
$8.11
52-Week Range:
$2.36
$8.11
Trevi Therapeutics Inc Stock (TRVI) Company Profile
Name
Trevi Therapeutics Inc
Sector
Industry
Phone
203-304-2499
Address
195 CHURCH STREET, NEW HAVEN, CT
Compare TRVI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TRVI
Trevi Therapeutics Inc
|
7.87 | 954.56M | 0 | -29.07M | -31.85M | -0.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Trevi Therapeutics Inc Stock (TRVI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-01-25 | Initiated | Cantor Fitzgerald | Overweight |
| May-28-25 | Initiated | H.C. Wainwright | Buy |
| Mar-10-25 | Reiterated | Needham | Buy |
| Mar-10-25 | Upgrade | Raymond James | Outperform → Strong Buy |
| Dec-12-24 | Reiterated | H.C. Wainwright | Buy |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Aug-30-24 | Initiated | H.C. Wainwright | Buy |
| Aug-30-24 | Initiated | Raymond James | Outperform |
| Jun-13-24 | Initiated | Rodman & Renshaw | Buy |
| Apr-12-23 | Initiated | B. Riley Securities | Buy |
| Nov-22-22 | Initiated | SVB Leerink | Outperform |
| Jun-03-19 | Initiated | BMO Capital Markets | Outperform |
| Jun-03-19 | Initiated | Needham | Buy |
| Jun-03-19 | Initiated | SVB Leerink | Outperform |
| Jun-03-19 | Initiated | Stifel | Buy |
View All
Trevi Therapeutics Inc Stock (TRVI) Latest News
Trevi Therapeutics Inc. Stock Analysis and ForecastUnbelievable profit margins - PrintWeekIndia
What analysts say about Trevi Therapeutics Inc. stockConsistent wealth multiplication - PrintWeekIndia
What drives Trevi Therapeutics Inc. stock priceUnprecedented profit potential - PrintWeekIndia
Is Trevi Therapeutics Inc. a good long term investmentHigh-profit trading signals - Autocar Professional
Will Trevi Therapeutics Inc. stock split in the near futureMarket-leading growth rates - jammulinksnews.com
How Trevi Therapeutics Inc. stock reacts to Fed policy changesRapid growth trajectories - jammulinksnews.com
Should I buy Trevi Therapeutics Inc. stock before earningsTurbocharged investment results - jammulinksnews.com
The Business Case For Buying Trevi Therapeutics Inc (NASDAQ: TRVI) Stock Now - Stocksregister
Trevi Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference - Seeking Alpha
Trevi Therapeutics to Attend Leerink Partners Therapeutics Forum: I&I and Metabolism - Eastern Progress
How Trevi Therapeutics Inc. stock performs during market volatilityFree Access to Investors Club - Newser
Trevi Therapeutics, Inc.'s (NASDAQ:TRVI) high institutional ownership speaks for itself as stock continues to impress, up 17% over last week - simplywall.st
Why Trevi Therapeutics Inc. stock attracts strong analyst attentionSolid Return Trade Selections - Newser
What makes Trevi Therapeutics Inc. stock price move sharplyFree Smart Investment Opportunities - Newser
Trevi Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering Use of Haduvio™ (nalbuphine ER) for the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis - The Globe and Mail
Trevi Therapeutics (TRVI) Price Target Predicts 231.05% Upside Potential - AInvest
Wall Street Analysts Predict a 231.05% Upside in Trevi Therapeutics (TRVI): Here's What You Should Know - Yahoo Finance
31,359 Shares in Trevi Therapeutics, Inc. (NASDAQ:TRVI) Purchased by Vontobel Holding Ltd. - Defense World
Cantor Fitzgerald Comments on TRVI FY2025 Earnings - Defense World
Trevi Therapeutics to Attend Leerink Partners Therapeutics Forum: I&I and Metabolism | TRVI Stock News - GuruFocus
Trevi Therapeutics to Attend Leerink Partners Therapeutics Forum: I&I and Metabolism. - AInvest
Trevi Therapeutics, Inc.(NasdaqGM: TRVI) dropped from Russell 3000 Value Index - MarketScreener
Cough in Idiopathic Pulmonary Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Algernon Pharma, Seyltx, Melius Pharma, NeRRe Therapeutics, Trevi Therapeutics - Barchart.com
TRVI STOCKHOLDER ALERT: Kaskela Law LLC Announces Investigation of Trevi Therapeutics, Inc. ... - Bluefield Daily Telegraph
Trevi Therapeutics Stockholders Approve Key Amendments - TipRanks
Leerink Partnrs Issues Optimistic Estimate for TRVI Earnings - Defense World
Trevi Therapeutics Inc Stock (TRVI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.97%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):